Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

Clinical pharmacology and therapeutics - 1 Aug 2013

Pussegoda K, Ross C J, Visscher H, Yazdanpanah M, Brooks B, Rassekh S R, Zada Y F, Dubé M-P, Carleton B C, Hayden M R

Abstract excerpt

Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumors. A serious complication of cisplatin treatment is permanent hearing loss. The aim of this study was to replicate previous genetic findings in an independent cohort of 155 pediatric patients. Associations were replicated for genetic variants in TPMT (rs12201199, P = 0.0013, odds ratio (OR) 6.1) and ABCC3 (rs1051640, P = 0.036, OR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Age Factors
Share to Catechol O-Methyltransferase
Share to Cisplatin
Share to Dose-Response Relationship, Drug
Share to Hearing Loss
Share to Methyltransferases
Share to Multidrug Resistance-Associated Proteins
Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 23588304
DOI: 10.1038/clpt.2013.80
PMCID: PMC4006820

Genes

ABCC3
TPMT
COMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.PMID 23588304Read ↗

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.Semantic proximity Read ↗

Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.Semantic proximity Read ↗

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.Semantic proximity Read ↗

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.Semantic proximity Read ↗

Genetic markers of cisplatin-induced hearing loss in children.Semantic proximity Read ↗

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.Semantic proximity Read ↗

Pharmacogenomics of cisplatin-induced ototoxicity.Semantic proximity Read ↗

Genetic variants associated with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.Semantic proximity Read ↗

Challenges in interpreting the evidence for genetic predictors of ototoxicity.Semantic proximity Read ↗

Otoprotection in Children Treated for Cancer: A CODEPEH Review Using PRISMA Methodology on Pharmacological Agents, Biomarkers and Genetic SusceptibilitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.